Titulo:
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance
.
Sumario:
Los ingresos a las unidades de cuidados intensivos (UCI) de pacientes con neoplasias hematológicas (NH) suelen ser comunes. Las intervenciones van encaminadas al manejo agudo (soporte ventilatorio, vasopresor); otra intervención es la quimioterapia (QT). La literatura relacionada con la mortalidad en pacientes con NH que reciben QT en UCI es escasa. Objetivo: resumir la información disponible sobre la mortalidad en pacientes con NH que reciben quimioterapia QT en la unidad de cuidados intensivos UCI. Métodos: se analizaron estudios publicados entre 2011 y 2021 de pacientes con NH ingresados en UCI, que hayan recibido QT durante su estancia. Las bases de datos exploradas fueron: PubMed, Scielo, LILACS, Biblioteca Cochrane, Science Direct y G... Ver más
Guardado en:
2256-2877
2256-2915
8
2022-05-02
Revista Colombiana de Hematología y Oncología - 2022
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
metarevistapublica_acho_revistacolombianadehematologiayoncologia_27_article_380 |
|---|---|
| record_format |
ojs |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| spellingShingle |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance Villalobos Caballero, Carlos Alexis Espinosa Redondo, Daniel Lorenzo Neoplasias hematológicas mortalidad unidad de cuidados intensivos estado crítico quimioterapia Hematological neoplasm mortality intensive care unit critically ill chemotherapy |
| title_short |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| title_full |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| title_fullStr |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| title_full_unstemmed |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| title_sort |
mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance |
| title_eng |
Mortality in patients with hematological neoplasms receiving chemotherapy in the intensive care unit: a scope review. |
| description |
Los ingresos a las unidades de cuidados intensivos (UCI) de pacientes con neoplasias hematológicas (NH) suelen ser comunes. Las intervenciones van encaminadas al manejo agudo (soporte ventilatorio, vasopresor); otra intervención es la quimioterapia (QT). La literatura relacionada con la mortalidad en pacientes con NH que reciben QT en UCI es escasa. Objetivo: resumir la información disponible sobre la mortalidad en pacientes con NH que reciben quimioterapia QT en la unidad de cuidados intensivos UCI. Métodos: se analizaron estudios publicados entre 2011 y 2021 de pacientes con NH ingresados en UCI, que hayan recibido QT durante su estancia. Las bases de datos exploradas fueron: PubMed, Scielo, LILACS, Biblioteca Cochrane, Science Direct y Google Scholar. La revisión se llevó a cabo de acuerdo a la metodología del Instituto Joanna Brigss (JBI) para revisiones de alcance, adhiriéndose a las guías PRISMA-ScR. Resultados: se incluyeron 10 artículos en la revisión. Las cifras de mortalidad oscilan entre 25 y 76.5 %. El linfoma con un 50 %, resultó ser la NH más prevalente. Las indicaciones de QT en UCI fueron como tratamiento de la patología de base o como soporte vital. Conclusión: la QT es una opción factible en pacientes con NH seleccionados al interior de las UCI. Sin embargo, se requieren estudios prospectivos para corroborar los hallazgos.
|
| description_eng |
Admissions to the intensive care unit (ICU) of patients with hematological malignancies (NH) are usually common. The interventions are aimed at acute management (ventilatory support, vasopressor); another intervention is chemotherapy (CT). The literature related to mortality in patients with NH who receive CT in the ICU is poor. Objective: To summarize the information available on mortality in patients with HN receiving CT in the ICU. Methods: Studies published between 2011 and 2021 of patients with NH admitted to the ICU who received CT during their stay were analyzed. The databases PubMed, Scielo, LILACS, Cochrane Library, Science Direct and Google Scholar were explored. The review was carried out according to the Joanna Brigss Institute (JBI) methodology for scoping reviews, adhering to the PRISMA-ScR guidelines. Results: 10 articles were included. Mortality was between 25 and 76.5%. Lymphoma was, with 50%, the most prevalent HN. The indications for CT in the ICU were as a treatment for the underlying pathology or as life support. Conclusion: CT is a feasible option in patients with NH selected within the ICU, However, prospective studies are required to corroborate the findings.
|
| author |
Villalobos Caballero, Carlos Alexis Espinosa Redondo, Daniel Lorenzo |
| author_facet |
Villalobos Caballero, Carlos Alexis Espinosa Redondo, Daniel Lorenzo |
| topicspa_str_mv |
Neoplasias hematológicas mortalidad unidad de cuidados intensivos estado crítico quimioterapia |
| topic |
Neoplasias hematológicas mortalidad unidad de cuidados intensivos estado crítico quimioterapia Hematological neoplasm mortality intensive care unit critically ill chemotherapy |
| topic_facet |
Neoplasias hematológicas mortalidad unidad de cuidados intensivos estado crítico quimioterapia Hematological neoplasm mortality intensive care unit critically ill chemotherapy |
| citationvolume |
8 |
| citationissue |
2 |
| citationedition |
Núm. 2 , Año 2021 : Julio-Diciembre |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/380 |
| language |
spa |
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-nd/4.0 Revista Colombiana de Hematología y Oncología - 2022 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| references |
Batista JL, Birmann BM, Meyer EM. Epidemiology of Hematologic Malignancies. En: Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Bríd M. (Eds). Pathology and Epidemiology of Cancer. Springer. [Internet]. Disponible en: https://doi.org/10.1007/978-3-319-35153-7_29. 2017. 2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. [Internet]. 2011;105(11):1684-92. Disponible en: https://doi.org/10.1038/bjc.2011.450 3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. [Internet]. 2016; 127(20):2391-405. Disponible en: https://doi.org/10.1182/blood-2016-03-643544 4. Global Cancer Observatory (GCO). [Internet]. 2020. Disponible en: https://gco.iarc.fr/ 5. Vijenthira A, Chiu N, Jacobson D, Freedman Z, Cheung M, Goddard S, et al. Predictors of intensive care unit admission in patients with hematologic malignancy. Sci Rep. [Internet]. 2020;10:21145. Disponible en: https://doi.org/10.1038/s41598-020-78114-7 6. De Vries VA, Müller M, Arbous MS, Biemond BJ, Blijlevens N, Kusadasi N, et al. Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. Crit Care Med. [Internet]. 2019; 47(2). Disponible en: https://doi.org/10.1097/CCM.0000000000003526 7. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet. [Internet]. 2002;360:1131–5. Disponible en: https://doi.org/10.1016/S0140-6736(02)11199-8 8. Gasparovic VG, Medic MMG, Gornik IG. Is admission of hematologic malignancies in the ICU justified? Crit Care. [Internet]. 2015;19(Suppl 1). Disponible en: https://doi.org/10.1186/cc14618 9. Magid T, Haase N, Andersen J, Nielsen O, Bonde J. Intensive care of haematological patients. Dan Med J. [Internet]. 2012;59(3):A4395. Disponible en: https://www.researchgate.net/publication/221879818_Intensive_care_of_haematological_patients 10. Kusadasi N, Müller M, van Westerloo DJ, Broers A, Hilkens M, Blijlevens. The management of critically ill patients with haematological malignancies. Neth. J. Med. [Internet]. 2017;75(7):265–71. Disponible en: https://www.njmonline.nl/getpdf.php?t=i&id=208 11. Van Beers EJ, Müller MC, Vlaar AP, Spanjaard L, Van den Bergh WH. Haematological malignancy in the intensive care unit: microbiology results and mortality. Eur J Haematol. [Internet]. 2016;97(3):271–7. Disponible en: https://doi.org/10.1111/ejh.12721. 12. Assi HI, Halim NA, Alameh I, Khoury J, Nahra V, Sukhon F, et al. Outcomes of Patients with Malignancy Admitted to the Intensive Care Units: A Prospective Study. Critical care research and practice. Crit. Care Res. Pract. [Internet]. 2021;4792309. Disponible en: https://doi.org/10.1155/2021/4792309 Moors I, Pène F, Lengline E, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr. Opin. Crit. Care. [Internet]. 2015;21(6):559-68. Disponible en: https://doi.org/10.1097/mcc.0000000000000254 14. Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med. [Internet]. 2006;32(1):93–9. Disponible en: https://doi.org/10.1007/s00134-005-2836-5 15. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping Reviews (2020 version). In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis, JBI, 2020. Disponible en: https://doi.org/10.46658/JBIMES-20-12 16. Stevinson C, Lawlor DA. Searching multiple databases for systematic reviews: added value or diminishing returns? Complementary therapies in medicine. [Internet]. 2004;12(4):228–32. Disponible en: https://doi.org/10.1016/j.ctim.2004.09.003 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. [Internet]. 2018;169:467–73. Disponible en: https://doi.org/10.7326/M18-0850 18. Lengliné E, Raffoux E, Lemiale V, Darmon M, Canet E, Boissel N, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. [Internet]. 2012;53(7):1352–9. Disponible en: https://doi.org/10.3109/10428194.2011.649752 19. De Oliveira MCF, Ferreira JC, Nassar AP, Dettino ALA, Caruso P. Impact of Urgent Chemotherapy in Critically Ill Patients. Journal of intensive care medicine. [Internet]. 2020;35(4):347–53. Disponible en: https://doi.org/10.1177/0885066617748602 20. Pastores SM, Goldman D, Shaz DJ, Kostelecky N, Daley RJ, Peterson TJ, et al. Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer. [Internet]. 2018;124(14). Disponible en: https://doi.org/10.1002/cncr.31409 21. Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, et al. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. [Internet]. 2011;19(4):491–5. Disponible en: https://doi.org/10.1007/s00520-010-0841-x 22. Wohlfarth P, Staudinger T, Sperr WR, Bojic A, Robak O, Hermann A, et al. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol. [Internet]. 2014;93(10):1629–36. Disponible en: https://doi.org/10.1007/s00277-014-2141-x 23. Moors I, Pène F, Lengline E, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr Opin Crit Care. [Internet]. 2015;21(6):559–68. Disponible en: https://doi.org/10.1097/MCC.0000000000000254 24. Cherruault M, Le Goff, M, Tamburini J, Pène F. Urgent Chemotherapy in Sepsis-Like Shock Related to Hematologic Malignancies. Crit Care Med. [Internet]. 2018;46(5):e465–e8. Disponible en: https://doi.org/10.1097/CCM.0000000000002990 25. Kanji S, MacLean, E., Rashid, F. J., Pittman, M., Trinacty, M., Allan, D, et al. Chemotherapy in the Intensive Care Unit: An Evaluation of Context and Outcomes. Can J Hosp Pharm. [Internet]. 2020;73(4):279–87. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556399/ 26. Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium- a groupe de recherche respiratoire en réanimation onco-hématologique study. Am J Clin Oncol. [Internet]. 2013; 31(22):2810–8. Disponible en: https://doi.org/10.1200/JCO.2012.47.2365 27. Bisbal M, Darmon M, Saillard C, Mallet V, Mouliade C, Lemiale V, et al. Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset. J Crit Care. [Internet]. 2021;62:88-93. Disponible en: https://doi.org/10.1016/j.jcrc.2020.11.023 28. Akkoç I, Yücetaş E, İşitemiz I, Toptaş M, Tas A, Sen O, et al. Mortality Rate In Intensive Care Units of Tertiary Health Institutions and Identifying Risk Factors: Analysis of 3945 Patients. Bezmialem sci. [Internet]. 2017;5:116-20. Disponible en: https://doi.org/10.14235/bs.2017.1102 29. Darmon M, Guillaume T, Ciroldi M, de Miranda S, Galicier L, Raffoux E, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med. [Internet]. 2005;33:2488–93. Disponible en: https://doi.org/10.1097/01.ccm.0000181728.13354.0a 30. Azoulay E, Schellongowski, P, Darmon M, Bauer PR, Benoit D, Depuydt, P, et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. [Internet]. 2017;43(9):1366–82. Disponible en: https://doi.org/10.1007/s00134-017-4884-z 31. Driessen R, Heijnen N, Hulsewe R, Holtkamp J, Winkens B, van de Poll M, et al. Early ICU-mortality in sepsis: causes, influencing factors and variability in clinical judgement: a retrospective cohort study. Infect Dis (Lond). [Internet]. 2021;53(1):61–8. Disponible en: https://doi.org/10.1080/23744235.2020.1821912 32. Kingsley A, Benedict N, Idongesit A, Okon Bassey B, Effiong O, Emem P, et al. Epidemiological Pattern of Adult Haematological Malignancies in a Tertiary Hospital in Cross River State. Int Res J Oncol. [Internet]. 2019;2(1):2-9. Disponible en: https://www.journalirjo.com/index.php/IRJO/article/view/30095 |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2022-05-02 |
| date_accessioned |
2022-05-02T16:40:25Z |
| date_available |
2022-05-02T16:40:25Z |
| url |
https://revista.acho.info/index.php/acho/article/view/380 |
| url_doi |
https://doi.org/10.51643/22562915.380 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.380 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/380/379 |
| _version_ |
1811200926598299648 |
| spelling |
Mortalidad en pacientes con neoplasias hematológicas que reciben quimioterapia en la unidad de cuidados intensivos: una revisión de alcance Mortality in patients with hematological neoplasms receiving chemotherapy in the intensive care unit: a scope review. Los ingresos a las unidades de cuidados intensivos (UCI) de pacientes con neoplasias hematológicas (NH) suelen ser comunes. Las intervenciones van encaminadas al manejo agudo (soporte ventilatorio, vasopresor); otra intervención es la quimioterapia (QT). La literatura relacionada con la mortalidad en pacientes con NH que reciben QT en UCI es escasa. Objetivo: resumir la información disponible sobre la mortalidad en pacientes con NH que reciben quimioterapia QT en la unidad de cuidados intensivos UCI. Métodos: se analizaron estudios publicados entre 2011 y 2021 de pacientes con NH ingresados en UCI, que hayan recibido QT durante su estancia. Las bases de datos exploradas fueron: PubMed, Scielo, LILACS, Biblioteca Cochrane, Science Direct y Google Scholar. La revisión se llevó a cabo de acuerdo a la metodología del Instituto Joanna Brigss (JBI) para revisiones de alcance, adhiriéndose a las guías PRISMA-ScR. Resultados: se incluyeron 10 artículos en la revisión. Las cifras de mortalidad oscilan entre 25 y 76.5 %. El linfoma con un 50 %, resultó ser la NH más prevalente. Las indicaciones de QT en UCI fueron como tratamiento de la patología de base o como soporte vital. Conclusión: la QT es una opción factible en pacientes con NH seleccionados al interior de las UCI. Sin embargo, se requieren estudios prospectivos para corroborar los hallazgos. Admissions to the intensive care unit (ICU) of patients with hematological malignancies (NH) are usually common. The interventions are aimed at acute management (ventilatory support, vasopressor); another intervention is chemotherapy (CT). The literature related to mortality in patients with NH who receive CT in the ICU is poor. Objective: To summarize the information available on mortality in patients with HN receiving CT in the ICU. Methods: Studies published between 2011 and 2021 of patients with NH admitted to the ICU who received CT during their stay were analyzed. The databases PubMed, Scielo, LILACS, Cochrane Library, Science Direct and Google Scholar were explored. The review was carried out according to the Joanna Brigss Institute (JBI) methodology for scoping reviews, adhering to the PRISMA-ScR guidelines. Results: 10 articles were included. Mortality was between 25 and 76.5%. Lymphoma was, with 50%, the most prevalent HN. The indications for CT in the ICU were as a treatment for the underlying pathology or as life support. Conclusion: CT is a feasible option in patients with NH selected within the ICU, However, prospective studies are required to corroborate the findings. Villalobos Caballero, Carlos Alexis Espinosa Redondo, Daniel Lorenzo Neoplasias hematológicas mortalidad unidad de cuidados intensivos estado crítico quimioterapia Hematological neoplasm mortality intensive care unit critically ill chemotherapy 8 2 Núm. 2 , Año 2021 : Julio-Diciembre Artículo de revista Journal article 2022-05-02T16:40:25Z 2022-05-02T16:40:25Z 2022-05-02 application/pdf Asociación Colombiana de Hematología y Oncología (ACHO) Revista Colombiana de Hematología y Oncología 2256-2877 2256-2915 https://revista.acho.info/index.php/acho/article/view/380 10.51643/22562915.380 https://doi.org/10.51643/22562915.380 spa https://creativecommons.org/licenses/by-nc-nd/4.0 Revista Colombiana de Hematología y Oncología - 2022 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. Batista JL, Birmann BM, Meyer EM. Epidemiology of Hematologic Malignancies. En: Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Bríd M. (Eds). Pathology and Epidemiology of Cancer. Springer. [Internet]. Disponible en: https://doi.org/10.1007/978-3-319-35153-7_29. 2017. 2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. [Internet]. 2011;105(11):1684-92. Disponible en: https://doi.org/10.1038/bjc.2011.450 3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. [Internet]. 2016; 127(20):2391-405. Disponible en: https://doi.org/10.1182/blood-2016-03-643544 4. Global Cancer Observatory (GCO). [Internet]. 2020. Disponible en: https://gco.iarc.fr/ 5. Vijenthira A, Chiu N, Jacobson D, Freedman Z, Cheung M, Goddard S, et al. Predictors of intensive care unit admission in patients with hematologic malignancy. Sci Rep. [Internet]. 2020;10:21145. Disponible en: https://doi.org/10.1038/s41598-020-78114-7 6. De Vries VA, Müller M, Arbous MS, Biemond BJ, Blijlevens N, Kusadasi N, et al. Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. Crit Care Med. [Internet]. 2019; 47(2). Disponible en: https://doi.org/10.1097/CCM.0000000000003526 7. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet. [Internet]. 2002;360:1131–5. Disponible en: https://doi.org/10.1016/S0140-6736(02)11199-8 8. Gasparovic VG, Medic MMG, Gornik IG. Is admission of hematologic malignancies in the ICU justified? Crit Care. [Internet]. 2015;19(Suppl 1). Disponible en: https://doi.org/10.1186/cc14618 9. Magid T, Haase N, Andersen J, Nielsen O, Bonde J. Intensive care of haematological patients. Dan Med J. [Internet]. 2012;59(3):A4395. Disponible en: https://www.researchgate.net/publication/221879818_Intensive_care_of_haematological_patients 10. Kusadasi N, Müller M, van Westerloo DJ, Broers A, Hilkens M, Blijlevens. The management of critically ill patients with haematological malignancies. Neth. J. Med. [Internet]. 2017;75(7):265–71. Disponible en: https://www.njmonline.nl/getpdf.php?t=i&id=208 11. Van Beers EJ, Müller MC, Vlaar AP, Spanjaard L, Van den Bergh WH. Haematological malignancy in the intensive care unit: microbiology results and mortality. Eur J Haematol. [Internet]. 2016;97(3):271–7. Disponible en: https://doi.org/10.1111/ejh.12721. 12. Assi HI, Halim NA, Alameh I, Khoury J, Nahra V, Sukhon F, et al. Outcomes of Patients with Malignancy Admitted to the Intensive Care Units: A Prospective Study. Critical care research and practice. Crit. Care Res. Pract. [Internet]. 2021;4792309. Disponible en: https://doi.org/10.1155/2021/4792309 Moors I, Pène F, Lengline E, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr. Opin. Crit. Care. [Internet]. 2015;21(6):559-68. Disponible en: https://doi.org/10.1097/mcc.0000000000000254 14. Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med. [Internet]. 2006;32(1):93–9. Disponible en: https://doi.org/10.1007/s00134-005-2836-5 15. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping Reviews (2020 version). In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis, JBI, 2020. Disponible en: https://doi.org/10.46658/JBIMES-20-12 16. Stevinson C, Lawlor DA. Searching multiple databases for systematic reviews: added value or diminishing returns? Complementary therapies in medicine. [Internet]. 2004;12(4):228–32. Disponible en: https://doi.org/10.1016/j.ctim.2004.09.003 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. [Internet]. 2018;169:467–73. Disponible en: https://doi.org/10.7326/M18-0850 18. Lengliné E, Raffoux E, Lemiale V, Darmon M, Canet E, Boissel N, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. [Internet]. 2012;53(7):1352–9. Disponible en: https://doi.org/10.3109/10428194.2011.649752 19. De Oliveira MCF, Ferreira JC, Nassar AP, Dettino ALA, Caruso P. Impact of Urgent Chemotherapy in Critically Ill Patients. Journal of intensive care medicine. [Internet]. 2020;35(4):347–53. Disponible en: https://doi.org/10.1177/0885066617748602 20. Pastores SM, Goldman D, Shaz DJ, Kostelecky N, Daley RJ, Peterson TJ, et al. Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit. Cancer. [Internet]. 2018;124(14). Disponible en: https://doi.org/10.1002/cncr.31409 21. Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, et al. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. [Internet]. 2011;19(4):491–5. Disponible en: https://doi.org/10.1007/s00520-010-0841-x 22. Wohlfarth P, Staudinger T, Sperr WR, Bojic A, Robak O, Hermann A, et al. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol. [Internet]. 2014;93(10):1629–36. Disponible en: https://doi.org/10.1007/s00277-014-2141-x 23. Moors I, Pène F, Lengline E, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr Opin Crit Care. [Internet]. 2015;21(6):559–68. Disponible en: https://doi.org/10.1097/MCC.0000000000000254 24. Cherruault M, Le Goff, M, Tamburini J, Pène F. Urgent Chemotherapy in Sepsis-Like Shock Related to Hematologic Malignancies. Crit Care Med. [Internet]. 2018;46(5):e465–e8. Disponible en: https://doi.org/10.1097/CCM.0000000000002990 25. Kanji S, MacLean, E., Rashid, F. J., Pittman, M., Trinacty, M., Allan, D, et al. Chemotherapy in the Intensive Care Unit: An Evaluation of Context and Outcomes. Can J Hosp Pharm. [Internet]. 2020;73(4):279–87. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556399/ 26. Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium- a groupe de recherche respiratoire en réanimation onco-hématologique study. Am J Clin Oncol. [Internet]. 2013; 31(22):2810–8. Disponible en: https://doi.org/10.1200/JCO.2012.47.2365 27. Bisbal M, Darmon M, Saillard C, Mallet V, Mouliade C, Lemiale V, et al. Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset. J Crit Care. [Internet]. 2021;62:88-93. Disponible en: https://doi.org/10.1016/j.jcrc.2020.11.023 28. Akkoç I, Yücetaş E, İşitemiz I, Toptaş M, Tas A, Sen O, et al. Mortality Rate In Intensive Care Units of Tertiary Health Institutions and Identifying Risk Factors: Analysis of 3945 Patients. Bezmialem sci. [Internet]. 2017;5:116-20. Disponible en: https://doi.org/10.14235/bs.2017.1102 29. Darmon M, Guillaume T, Ciroldi M, de Miranda S, Galicier L, Raffoux E, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med. [Internet]. 2005;33:2488–93. Disponible en: https://doi.org/10.1097/01.ccm.0000181728.13354.0a 30. Azoulay E, Schellongowski, P, Darmon M, Bauer PR, Benoit D, Depuydt, P, et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. [Internet]. 2017;43(9):1366–82. Disponible en: https://doi.org/10.1007/s00134-017-4884-z 31. Driessen R, Heijnen N, Hulsewe R, Holtkamp J, Winkens B, van de Poll M, et al. Early ICU-mortality in sepsis: causes, influencing factors and variability in clinical judgement: a retrospective cohort study. Infect Dis (Lond). [Internet]. 2021;53(1):61–8. Disponible en: https://doi.org/10.1080/23744235.2020.1821912 32. Kingsley A, Benedict N, Idongesit A, Okon Bassey B, Effiong O, Emem P, et al. Epidemiological Pattern of Adult Haematological Malignancies in a Tertiary Hospital in Cross River State. Int Res J Oncol. [Internet]. 2019;2(1):2-9. Disponible en: https://www.journalirjo.com/index.php/IRJO/article/view/30095 https://revista.acho.info/index.php/acho/article/download/380/379 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/redcol/resource_type/ARTREF info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication |